IC-OS Topics in Cardio-Oncology Webinar

Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis. He was recently at Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current President of the International Cardio-Oncology Society (ICOS),www.IC-OS.org, which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

Joshua Mitchell, MD, MSCI is an Assistant Professor of Medicine and Director of the Cardio-Oncology Fellowship at the Cardio-Oncology Center of Excellence, Washington University School of Medicine in St. Louis. Prior to coming to Washington University in 2015, he served 11 years in the US Army, deploying with the 82nd Airborne Division and the 75th Ranger Regiment, earning two Bronze Start Medals, and reaching the rank of Major. He is currently a member of the ICOS Scientific Committee and recently helped lead the 2021 ICOS expert consensus statement for cardiovascular disease screening in radiation survivors. He also serves on the JACC:Cardio-Oncology editorial board and is the Co-Chair for the ACC Cardio-Oncology working group. His clinical and research interests include better characterizing and understanding cardiovascular disease associated with cancer treatment, and the diagnosis of management of cardiac amyloidosis. His research has also focused on the use of coronary artery calcium to improve risk prediction and help target preventive therapy. As the Cardio-Oncology fellowship director at Washington University in St. Louis, he has directed the training and development for full year fellows, rotations for internal cardiology fellows, and rotations for both external cardiology fellows and for board certified cardiologists looking for additional training in Cardio-Oncology to improve their practice.

Dr. Stephen Casselli is an executive director at International Cardio-Oncology Society.

Dr. Dent attended McMaster University Medical School in Hamilton, Ontario, Canada and completed her residency training in Internal Medicine and Medical Oncology at the Ottawa Hospital, University of Ottawa, Ontario, Canada. She subsequently completed a post graduate research fellowship in clinical trials at the Canadian Cancer Trials Group (CCTG) in Kingston, Ontario, and was appointed as a staff medical oncologist at the Northwestern Ontario Cancer Center in Thunder Bay, Ontario. In 2001, Dr. Dent returned to Ottawa, where she specialized in the treatment of breast cancer. In 2008, Dr. Dent, working with her cardiology colleagues, established a multidisciplinary cardio-oncology clinic in Ottawa; the first of its kind in Canada. In 2011, she founded the Canadian Cardiac Oncology Network (CONN), a not-for-profit organization devoted to optimization of cancer care for patients without compromising cardiovascular health. In 2015, Dr. Dent launched the Global Cardio-Oncology Summit (GCOS), an annual meeting which now attracts oncologists, cardiologists, and allied health care providers from more than 23 countries. Dr. Dent is recognized as a global leader in cardio-oncology. She has travelled extensively around the world sharing her knowledge and expertise on the potential impact of cancer treatment on cardiovascular health. She has published extensively in the area and has co-authored a number of position statements and clinical practice guidelines. Dr. Dent currently serves as an Executive Officer of the International Cardio-Oncology society (ICOS), an organization dedicated to bringing cardiologists, oncologists, and allied health care providers together, to improve the clinical care of patients and save lives. In September 2018, Dr. Dent accepted a staff position in medical oncology at Duke University, where she will continue her efforts in promoting clinical care, education and research in cardio-oncology.